register

News & Trends - Pharmaceuticals

AbbVie’s phase 3 wins for Humira successor Skyrizi

Health Industry Hub | January 22, 2021 |
[Total: 1    Average: 5/5]

Pharma News: AbbVie is in a race against time as patent expiry of its Humira inflammatory diseases blockbuster draws near in 2023.

The company’s follow-up drug Skyrizi (risankizumab) is important to AbbVie’s strategy to negotiate the $20 billion patent cliff from Humira, which has already seen sales decline outside of the US where it has already lost protection against less expensive competitors.

In AbbVie’s latest announcements, Skyrizi demonstrated significant improvements in clinical remission and endoscopic response in two Phase 3 Crohn’s Disease induction studies, ADVANCE and MOTIVATE. The ADVANCE study enrolled patients who had an inadequate response or were intolerant to conventional and/or biologic therapy. The MOTIVATE study evaluated patients who had responded inadequately or were intolerant to biologic therapy.

Additionally, Skyrizi’s Phase 3 study results from the KEEPsAKE-1 and KEEPsAKE-2 clinical trials demonstrated improvements in disease activity across joint and skin symptoms among psoriatic arthritis patients paving the way for a launch in additional indications.

With Skyrizi, AbbVie hopes to cover many of the indications where Humira has become standard therapy.

At the 39th Annual JP Morgan Healthcare Conference on 12 January 2021, AbbVie CEO Richard Gonzalez indicated that the company expects global sales of more than $7B for Skyrizi by 2025.

You may also like Changing MSL value proposition accelerated by the COVID-19 pandemic


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - Johnson & Johnson breaking down barriers to gender equality

Johnson & Johnson breaking down barriers to gender equality

Health Industry Hub | February 26, 2021 |

MedTech News: The Johnson & Johnson Family of Companies in Australia is pleased to announce that the company has been […]

More


Human Resources

Human Resource Management - National gender pay gap drops to 13.4%

National gender pay gap drops to 13.4%

Health Industry Hub | February 26, 2021 |

Human Resources: The Workplace Gender Equality Agency announced today that that national gender pay gap has dropped to 13.4%, a decline […]

More


News & Trends - Medical Technology

MedTech News - Philips one of first MedTechs to become carbon neutral

Philips, one of first MedTechs to become carbon neutral

Health Industry Hub | February 26, 2021 |

MedTech News: Philips Healthcare Australia, a global leader in health technology, has successfully met all the targets set out in […]

More


Social Responsibility

Social Responsibility and Community Engagement - The race to win the 2021 Medicines Australia, Kosi Pharma-Cup

The race to win the 2021 Medicines Australia Kosi Pharma-Cup

Health Industry Hub | February 26, 2021 |

The countdown is on for Rare Cancer Australia’s Kosi Challenge and the battle to win the Pharma-Cup sponsored by Medicines […]

More